Recombinant Dna Technique Included In Method Of Making A Protein Or Polypeptide Patents (Class 435/69.1)
-
Patent number: 9260502Abstract: The present invention relates to novel insulin analogs comprising mutations at position A14 in the A chain and at positions B27, B28, B29 and B30 in the B chain and exhibiting resistance towards protease; a method for the preparation of such insulin analogs; insulin preparations containing the insulin analogs of the invention; and, a method of treating diabetes mellitus using these insulin analogs.Type: GrantFiled: March 13, 2009Date of Patent: February 16, 2016Assignee: Novo Nordisk A/SInventors: Peter Kresten Nielsen, Frantisek Hubalek, Inger Lautrup-Larsen, Per Balschmidt, Svend Ludvigsen, Thomas Børglum Kjeldsen
-
Patent number: 9260496Abstract: The present invention relates to fibronectin based scaffold domain protein that bind interleukin 23 (IL-23). The invention also relates to the use of the innovative proteins in therapeutic applications to treat autoimmune diseases. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.Type: GrantFiled: December 20, 2011Date of Patent: February 16, 2016Assignee: Bristol-Myers Squibb CompanyInventors: Ruchira Dasgupta, Steven Sheriff, Anzhi Wei, Vidhyashankar Ramamurthy, Alex Bush, Katie A. Russo, Linda Engle
-
Patent number: 9255285Abstract: The present invention demonstrates the utility of carbonic acid amides such as urea or its derivatives, carbamates, carbodiimides & thiocarbamides as nitrogenous supplements in fermentation media for production of recombinant proteins to achieve enhanced bioconversion rates and peptides like insulin and insulin analogs, exendin and enzymes such as lipase using methanol inducible fungal expression systems such as Pichia.Type: GrantFiled: January 23, 2014Date of Patent: February 9, 2016Assignee: Biocon LimitedInventors: Sanjay Tiwari, Mukesh Babuappa Patale, Saurabh Garg, Mayank Kumar Garg, Sulekha Joshi, Chittnalli Ramegowda Naveen Kumar, Bimal Kumar, Anuj Goel, Harish Iyer
-
Patent number: 9249423Abstract: RNA prepared by in vitro transcription using a polymerase chain reaction (PCR)-generated template can be introduced into a cell to modulate cell activity. This method is useful in de-differentiating somatic cells to pluripotent, multipotent, or unipotent cells; re-differentiating stem cells into differentiated cells; or reprogramming of somatic cells to modulate cell activities such as metabolism. Cells can also be transfected with inhibitory RNAs, such as small interfering RNA (siRNA) or micro RNA (miRNA), or combinations thereof to induce reprogramming of somatic cells. For example, target cells are isolated from a donor, contacted with one or more RNA's causing the cells to be de-differentiated, re-differentiated, or reprogrammed in vitro, and administered to a patient in need thereof. The resulting cells are useful for treating one or more symptoms of a variety of diseases and disorders, for organ regeneration, and for restoration of the immune system.Type: GrantFiled: February 2, 2011Date of Patent: February 2, 2016Assignee: Yale UniversityInventors: Peter M. Rabinovich, Sherman M. Weissman
-
Patent number: 9249204Abstract: This application is directed to chemokine-immunoglobulin fusion polypeptides and chemokine-polymer conjugates. The fusion polypeptides and conjugates can be used for treating chemokine receptor-mediated disorders and modulating inflammation, inflammatory cell motility, cancer cell motility, or cancer cell survival.Type: GrantFiled: February 3, 2015Date of Patent: February 2, 2016Assignee: JYANT TECHNOLOGIES, INC.Inventor: James W. Lillard, Jr.
-
Patent number: 9248112Abstract: The present invention relates to a haemodialysis solution or concentrate thereof comprising creatine compound(s) and the use of creatine compound(s) for preparing a dialysis solution or concentrate thereof. Furthermore, the present invention is directed to a method for preparing creatine-containing dialysis solutions and concentrates. In addition, the present invention is directed to a method for treating patients with dialysis dependent renal failure with creatine compounds and to provide a variety of significant health benefits and improvement of life quality parameters for dialysis patients. This is achieve by supporting and improving the physiological functions of the patients organs and cells via creatine compounds delivery to the patients, and by protecting organs and cells (specifically including blood cells) of these patients from deleterious effects of a variety of endogenous or exogenous cellular stressors that are linked to the disease state or to the clinical treatment modalities.Type: GrantFiled: March 10, 2010Date of Patent: February 2, 2016Assignee: CREARENE LTD.Inventors: Michael Möddel, Theo Wallimann
-
Patent number: 9243263Abstract: The present invention relates to steroidal ligands for use in nuclear receptor-based inducible gene expression systems. The invention further relates to methods of modulating the expression of genes of interest with a system containing one or more nuclear receptor complexes and one or more steroidal ligands. Further aspects include ligand compositions including therapeutic compositions.Type: GrantFiled: July 22, 2013Date of Patent: January 26, 2016Assignee: Intrexon CorporationInventors: Robert E. Hormann, Silvia Lapenna, Laurence Neil Dinan
-
Patent number: 9238819Abstract: Transgenic plants having increased growth rate and increase yield are disclosed, and methods for making the same. In one embodiment, the method comprises: transforming a plant or plant cell with a nucleic acid molecule comprising a plant kinase and/or phosphatase gene selected from NG6, NG21, NG24, NG28, and NG32, and over-expressing said kinase and/or phosphatase gene in the plant or plant cell.Type: GrantFiled: March 12, 2012Date of Patent: January 19, 2016Assignee: Versitech LimitedInventor: Boon Leong Lim
-
Patent number: 9238042Abstract: Provided are antisense oligonucleotides and other agents that target and modulate IL-17 and/or IL-23 signaling activity in a cell, compositions that comprise the same, and methods of use thereof. Also provided are animal models for identifying agents that modulate 17 and/or IL-23 signaling activity.Type: GrantFiled: May 13, 2011Date of Patent: January 19, 2016Assignee: Sarepta Therapeutics, Inc.Inventors: Frederick J. Schnell, Patrick L. Iversen, Dan V. Mourich, Gunnar J. Hanson
-
Patent number: 9234251Abstract: The invention discloses an isolated, biologically pure culture of Bacillus amyloliquefaciens strain NRRL B-50349 and its use as an environmentally desirable biofungicide. The invention also discloses a formulation comprising the bacterium and a method for controlling plant fungal diseases and infestation of fungal organisms utilizing the strain.Type: GrantFiled: March 18, 2011Date of Patent: January 12, 2016Assignee: Novozymes Biologicals, Inc.Inventors: Amy Snyder, Jessica Vance, Samuel Gnanmanickam
-
Patent number: 9234032Abstract: The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture.Type: GrantFiled: January 16, 2014Date of Patent: January 12, 2016Assignee: AbbVie Inc.Inventors: Itzcoatl A. Pla, Joseph G. Matuck, John C. Fann, Christof Schulz, Nichole A. Roy, David F. Bruton, James McIntire, Yu-hsiang D. Chang, Thomas Seewoester
-
Patent number: 9234213Abstract: The invention relates to engineered CRISPR/Cas9 systems for genomic modification in mammalian cells. The present specification describes the design and testing of a polynucleotide encoding the Streptococcus pyogenes (S. pyogenes) Cas9 protein, where the nucleotide sequence has been optimized for expression in mammalian cells. The specification also describes all-in-one systems for RNA-guided genome engineering in mammalian cells, including human cells.Type: GrantFiled: March 14, 2014Date of Patent: January 12, 2016Assignee: System Biosciences, LLCInventor: Fangting Wu
-
Patent number: 9234197Abstract: The present invention provides isolated polynucleotides that can serve as translation enhancing elements and their use in protein expression reagents and methods.Type: GrantFiled: October 26, 2012Date of Patent: January 12, 2016Assignee: Arizona Board of Regents, A Body Corporate of the State of Arizona for and on Behalf of Arizona State UniversityInventors: John Chaput, Bertram Jacobs, Brian Wellensiek, Julia Flores
-
Patent number: 9228174Abstract: Nucleic acids encoding Parvoviral Rep proteins with a mutated nuclear localization signal (NLS) are provided. Also provided is a nucleic acid comprising a nucleotide sequence encoding a Parvoviral Rep protein with a mutated zinc finger domain and a nucleic acid comprising a nucleotide sequence encoding a Parvoviral Rep protein comprising an amino acid mutation at position 43, 57, 79, 97, 120, 179, 305, 484, 493 or 571 with reference to SEQ ID NO: 2. Nucleic acid constructs and cells, such as insect cells, comprising the nucleic acids are provided as well as a method for producing a recombinant Parvoviral virion using the nucleic acids.Type: GrantFiled: March 11, 2011Date of Patent: January 5, 2016Assignee: UNIQURE IP B.V.Inventors: Yvet Noordman, Jacek Lubelski, Andrew Christian Bakker
-
Patent number: 9228218Abstract: The present invention relates to an expression vector for animal cells, comprising: (a) CSP-B (Cytotoxic Serine Protease-B) 5?-SAR (Scaffold or Matrix Attachment Region); (b) a promoter operable in animal cells; and (c) a polyadenylation sequence, and to a method for producing recombinant proteins using same. The vector of the present invention includes CSP-B 5?-SAR, and thus has the effect of overcoming the inhibition of gene expression according to the position of a foreign gene introduced into an animal cell, and significantly improving the expression rate of a target protein. The vector of the present invention effectively expresses recombinant proteins for drugs or antibodies in animal cells. The vector of the present invention and the method for producing recombinant proteins using same may be very usefully applied to the industrial mass production of drugs.Type: GrantFiled: May 21, 2012Date of Patent: January 5, 2016Assignee: CHONG KUN DANG PHARMACEUTICAL CORP.Inventors: Yeo-Wook Koh, Sang-Yong Lee, Su-Yon Kim, Seung-Kee Moon
-
Patent number: 9228190Abstract: A vector for constitutively expressing a high level of a target protein, and more particularly a RepE mutant protein containing a deletion of 21 amino acids in the C-terminal region of a RepE protein and a vector for constitutively expressing a high level of a target protein, which comprises a gene encoding the mutant protein. The constitutive high-level expression vector can stably express a high level of a target protein. Also, the surface expression vector can express a target protein on the surface of recombinant microorganisms while constitutively expressing a high level of the target protein, and thus will be useful for construction of an antigen for vaccines.Type: GrantFiled: January 7, 2010Date of Patent: January 5, 2016Assignees: Bioleaders Corporation, Kookmin University Industry-Academic Cooperation FoundationInventors: Moon-Hee Sung, Seung Pyo Hong, A Ri Jang
-
Patent number: 9228011Abstract: The present invention relates to the use of antibodies against the S100P protein for the prevention and/or treatment of cancer; and to methods and kits for diagnosing cancer in vitro by means of detecting the levels of S100P in a biofluid, preferably with an antibody. The invention also relates to specific anti-S100P monoclonal antibodies, hybridoma cell lines producing them and method for obtaining them, as well as to pharmaceutical compositions and conjugates containing them.Type: GrantFiled: January 17, 2012Date of Patent: January 5, 2016Assignee: Lykera Biomed SAInventors: José Luis Hernández Míguez, Jaume Adan Plana, Josep Maria Martínez Escolà, Marc Masa Álvarez, Ramon Messeguer Peypoch, Francesc Mitjans Prat, Sheila Dakhel Plaza, Antonio Coll Manzano, Rosa Ma Hervas Villegas, Carme Calvis Calpe, Laura Padilla García, Lourdes Tatiana Roque Navarro, Laura Barberà Ferrando, Manuel Rivas Cañas
-
Patent number: 9221882Abstract: We discovered that a biosynthetic polypeptide, consisting of at least about 50 proline (Pro) and alanine (Ala) amino acid residues, forms a random coil, and increases the stability of other compounds to which it is conjugated, such as small molecules and polypeptides. We describe such biosynthetic polypeptides, constructs containing such polypeptides, ways of making them, and their use.Type: GrantFiled: May 20, 2011Date of Patent: December 29, 2015Assignees: Technische Universitat Munchen, XL-Protein GmbHInventors: Arne Skerra, Uli Binder, Martin Schlapschy
-
Patent number: 9217168Abstract: Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using putrescine, are described.Type: GrantFiled: March 14, 2013Date of Patent: December 22, 2015Assignee: Momenta Pharmaceuticals, Inc.Inventor: Holly Prentice
-
Patent number: 9217017Abstract: The present invention relates to a method for coating an inert or naturally occurring material with a silk polypeptide. It further relates to a coated inert or naturally occurring material obtainable by said method and to uses thereof. It also relates to products comprising said coated material.Type: GrantFiled: December 7, 2010Date of Patent: December 22, 2015Assignee: Amsilk GmbHInventors: Axel H. Leimer, Lin Romer
-
Patent number: 9217150Abstract: The present invention provides a nucleic acid molecule comprising: (a) a nucleotide sequence as shown in SEQ ID No. 1; or (b) a nucleotide sequence which is the complement of SEQ ID No. 1; or (c) a nucleotide sequence which is degenerate with SEQ ID No. 1; or (d) a nucleotide sequence having at least 85% sequence identity (preferably at least 87%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity) with SEQ ID No. 1; or (e) a part of any one of (a) to (d), wherein said nucleic acid molecule encodes or is a complementary to a nucleic acid molecule encoding one or more polypeptides, or comprises or is complementary to a nucleic acid molecule comprising one or more genetic elements, having functional activity in the synthesis of a polyketide-based or macrolactam molecule.Type: GrantFiled: March 20, 2009Date of Patent: December 22, 2015Assignee: SINTEF TTO ASInventors: Hanne Jørgensen, Trond Erling Ellingsen, Kristin Fløgstad Degnes, Per Bruheim, Håvard Sletta, Espen Fjærvik, Geir Klinkenberg, Sergey Zotchev
-
Patent number: 9217026Abstract: Disclosed herein are methods and compositions for inactivation of the human glucocorticoid receptor (GR) gene by targeted cleavage of genomic DNA encoding the GR. Such methods and compositions are useful, for example, in therapeutic applications which require retention of immune function during glucocorticoid treatment.Type: GrantFiled: November 13, 2007Date of Patent: December 22, 2015Assignee: Sangamo BioSciences, Inc.Inventors: Andreas Reik, Michael Jensen, Michael C. Holmes, Philip D. Gregory, Dale Ando
-
Patent number: 9211325Abstract: Adjuvant compositions comprising specific 5mer polypeptides in combination with antigen delivery systems and/or immunostimulatory molecules, such as immunostimulatory nucleic acid sequences, for enhancing the immune response of a coadministered antigen, are described.Type: GrantFiled: March 15, 2013Date of Patent: December 15, 2015Assignee: Her Majesty the Queen in Right of Canada as Represented by the Minister of HealthInventors: Ami Patel, Darwyn Kobasa, Gary Kobinger, Shawn Babiuk
-
Patent number: 9205136Abstract: Methods of enhancing angiogenesis utilizing carboxy-terminal truncated human tyrosyl-tRNA synthetase (TyrRS) are disclosed. The truncated human TyrRS polypeptides comprise residues 1-364 or residues 1-343 of full length human TyrRS (SEQ ID NO: 2).Type: GrantFiled: January 10, 2014Date of Patent: December 8, 2015Assignee: The Scripps Research InstituteInventors: Paul Schimmel, Keisuke Wakasugi
-
Patent number: 9206454Abstract: The present invention relates to a genetically modified yeast cell comprising: —at least one recombinant promoter operably linked to at least one gene encoding a polypeptide or protein supporting the biosynthesis of polypeptides or proteins within said cell, said at least one gene being located at the native genomic locus of the genetically unmodified wild-type yeast cell, wherein the naturally occurring promoter of the at least one gene encoding the biosynthesis supporting polypeptide or protein is inactivated by at least one mutation within said naturally occurring promoter and, —a secretion cassette comprising a recombinant nucleic acid molecule encoding a protein or polypeptide of interest and a method for producing a recombinant protein or polypeptide of interest using such a cell.Type: GrantFiled: August 31, 2012Date of Patent: December 8, 2015Assignee: VTU HOLDING GMBHInventors: Roland Weis, Thomas Purkarthofer
-
Patent number: 9206398Abstract: The present invention relates to a method for purifying target protein which contains electron transfer protein, from a protein solution containing the target protein, by means of liquid chromatography. The liquid chromatography is performed as follows: First, the protein solution is introduced into a column which is filled with a packing agent, thereby causing the packing agent to bond to the target protein. Then, impurities are removed, and then the target protein is eluted from the packing agent in an eluent which contains a hydroxy-cholate. An example of the target protein is glucose dehydrogenase which contains a protein having glucose dehydrogenation activity. The liquid chromatography is performed as a combination of hydrophobic chromatography and anion exchange chromatography.Type: GrantFiled: December 1, 2011Date of Patent: December 8, 2015Assignee: ARKRAY, Inc.Inventors: Hideaki Yamaoka, Keisuke Kurosaka, Shido Kawase
-
Patent number: 9201971Abstract: A method includes determining a plurality of social objects, each social object having a link to a link object on a network. The method further includes applying a filter to the determined social objects in order to determine a plurality of filtered social objects, retrieving a copy of each of the link objects linked to by the plurality of filtered social objects, and generating, using the retrieved copies of the link objects linked to by the plurality of filtered social objects, a matrix comprising a plurality of vectors. The method further includes generating a singular value representation of the matrix by performing Singular Value Decomposition (SVD) on the matrix and storing the singular value representation of the matrix in one or more memory units.Type: GrantFiled: January 8, 2015Date of Patent: December 1, 2015Assignee: Brainspace CorporationInventors: Paul A. Jakubik, David Adam Hagar, David S. Copps
-
Patent number: 9198452Abstract: The present invention relates to a process for the production of a food product whereby an intermediate form of said food product comprises a pigment, which process comprises adding at least one enzyme that is effective in directly converting said pigment into a form which results in increasing the whiteness of at least part of the food product compared to the food product for which said enzyme is not added during its production. The invention also relates to food products obtained from the process of the invention.Type: GrantFiled: July 27, 2012Date of Patent: December 1, 2015Assignee: DSM IP ASSETS B.V.Inventors: Johanna Henrica Gerdina Maria Mutsaers, Thibaut José Wenzel, Lex De Boer, Albertus Alard Van Dijk, Rutger Jan Van Rooijen
-
Patent number: 9193793Abstract: The present disclosure provides proteins comprising antigen binding domains of antibodies that bind to human granulocyte-colony stimulating factor receptor.Type: GrantFiled: June 13, 2012Date of Patent: November 24, 2015Assignee: CSL LIMITEDInventors: Andrew Donald Nash, Arna Elizabeth Andrews, Manuel Baca, Kirsten Mae Edwards, Matthew Philip Hardy, Con Panousis, Felicity Meredith Dunlop
-
Patent number: 9187550Abstract: A lipid particle comprising an apolipoprotein, a phosphatidylcholine and a lipid, such as a phospholipid, fatty acid or steroid lipid. In one embodiment the lipid particle comprises only one apolipoprotein. In one embodiment the lipid particle is consisting of one apolipoprotein, a phospholipid, a lipid, and a detergent. In one embodiment the lipid is a second phosphatidylcholine, wherein the first phosphatidylcholine and the second phosphatidylcholine differ in one or two fatty acid residues or fatty acid residue derivatives which are esterified to the glycerol backbone of the phosphatidylcholine. In one embodiment the apolipoprotein is selected from an apolipoprotein that has the amino acid sequence selected from SEQ ID NO: 01, 02, 06, 66, and 67, or is a variant thereof that has at least 70% sequence identity with the selected sequence.Type: GrantFiled: August 25, 2011Date of Patent: November 17, 2015Assignee: Hoffman—La Roche Inc.Inventors: Martin Bader, Monika Baehner, Juergen Fingerle, Ulrich Kohnert, Jean-Luc Mary, Silke Mohl
-
Patent number: 9187758Abstract: Disclosed herein are zinc fingers comprising CCHC zinc coordinating residues. Also described are zinc finger proteins and fusion proteins comprising these CCHC zinc fingers as well as polynucleotides encoding these proteins. Methods of using these proteins for gene editing and gene regulation are also described.Type: GrantFiled: December 13, 2007Date of Patent: November 17, 2015Assignees: Sangamo BioSciences, Inc., Dow AgroSciences LLCInventors: Qihua C. Cai, Vipula K. Shukla, Joseph F. Petolino, Lisa W. Baker, Robbi J. Garrison, Ryan C. Blue, Jon C. Mitchell, Nicole L. Arnold, Sarah E. Worden, Jeffrey Miller, Fyodor Urnov
-
Patent number: 9187552Abstract: The present invention is directed to methods and compositions for the production of Fc-containing polypeptides having improved properties and comprising mutations at positions 243 and 264 of the Fc region.Type: GrantFiled: May 25, 2011Date of Patent: November 17, 2015Assignee: Merck Sharp & Dohme Corp.Inventors: Terrance A. Stadheim, Dongxing Zha, Liming Liu
-
Patent number: 9188587Abstract: The invention relates to a method of diagnosing an autoimmune neurological disorder in a mammal comprising the step of detecting, in a bodily fluid sample from the mammal, autoantibodies to an epitope of at least one Kv1-complex protein; and related methods, assay kits, isolated or purified autoantibody or antibody fragments, or uses thereof.Type: GrantFiled: October 26, 2009Date of Patent: November 17, 2015Assignee: ISIS INNOVATION LIMITEDInventor: Angela Vincent
-
Patent number: 9187537Abstract: There are provided a recombinant silk protein derived from sea anemones, a method for producing the same, and a composition for preparing a silk fiber including same. The recombinant silk protein derived from sea anemones has sequence features similar to genetic information of a silk protein derived from spiders and silkworms. Also, a large amount of recombinant silk protein derived from sea anemones may be produced from a transformant and it has good physical properties such as strength and elasticity. Therefore, the recombinant silk protein derived from sea anemones can be usefully applied in various industrial fields in which natural silk protein can be applied, and it is expected to create new industrial fields based on its distinctive mechanical properties.Type: GrantFiled: February 6, 2012Date of Patent: November 17, 2015Assignee: POSTECH ACADEMY-INDUSTRY FOUNDATION POHANG UNIVERSITY OF SCIENCE AND TECHNOLOGYInventors: Hyung Joon Cha, Yun Jung Yang, Yoo Seong Choi
-
Patent number: 9180205Abstract: Disclosed are methods, compositions and uses of high concentration antibody or immunoglobulin formulations for subcutaneous, intramuscular, transdermal or other local (regional) administration, in a volume of than 3, less than 2 or less than 1 ml. Preferably, the formulation contains a high concentration formulation (HCF) buffer comprising phosphate, citrate, polysorbate 80 and mannitol at a pH of about 5.2. The formulation more preferably comprises at least 100, 150, 200, 250 mg/ml or 300 mg/ml of antibody. The methods for preparing the high concentration formulation include ultrafiltration and diafiltration to concentrate the antibody and exchange the medium for HCF buffer. Other embodiments concern use of non-G1m1 (nG1m1) allotype antibodies, such as G1m3 and/or a nG1m1,2 antibodies. The nG1m1 antibodies show decreased immunogenicity compared to G1m1 antibodies.Type: GrantFiled: January 24, 2014Date of Patent: November 10, 2015Assignee: Immunomedics, Inc.Inventors: Li Zeng, Rohini Mitra, Edmund A. Rossi, Hans J. Hansen, David M. Goldenberg
-
Patent number: 9181556Abstract: The present invention relates to inducible transcription control sequences for the regulation of gene expression. Specifically, it relates to an transcription control sequence comprising at least two tet operator sequence motifs allowing the binding of tetracycline-dependent transcriptional regulators, wherein each of the tetracycline-dependent transcriptional regulators binds with respect to its neighbor to an opposite face of the DNA helix, and a minimal promoter comprising a TATA box which is linked at its 5? end to a general transcription factor binding site. Further, the present invention relates to a vector, a host cell, a plant or a non-human transgenic animal comprising the transcription control sequence. Also contemplated is a method for regulating the expression of a nucleic acid sequence being operatively linked to the transcription control sequence of the present invention in a host cell, a plant or a non-human transgenic animal.Type: GrantFiled: August 19, 2009Date of Patent: November 10, 2015Assignee: TET SYSTEMS GMBH & CO., KGInventors: Hermann Bujard, Rainer Loew
-
Patent number: 9181527Abstract: The invention is directed to modified T cells, methods of making and using isolated, modified T cells, and methods of using these isolated, modified T cells to address diseases and disorders. In one embodiment, this invention broadly relates to TCR-deficient T cells, isolated populations thereof, and compositions comprising the same. In another embodiment of the invention, these TCR-deficient T cells are designed to express a functional non-TCR receptor. The invention also pertains to methods of making said TCR-deficient T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said TCR-deficient T cells, populations thereof, or compositions comprising the same.Type: GrantFiled: October 29, 2010Date of Patent: November 10, 2015Assignee: The Trustees of Dartmouth CollegeInventor: Charles L. Sentman
-
Patent number: 9181585Abstract: The present invention relates to methods of genotyping for selecting an animal with a desired trait such as the level of monounsaturated fats in muscle tissue, the types and/or ratio of different monounsaturated fats in muscle tissue, marbling, carcass weight, meat quality, speed of finishing, feedlot efficiency and/or consumer preference. In particular the invention relates to methods of selecting an animal with a desired trait by analyzing the M-RIP, NT5M and/or TCAP genes for one or more polymorphisms.Type: GrantFiled: September 17, 2010Date of Patent: November 10, 2015Assignee: CY O'Connor Erade Village FoundationInventors: Roger Letts Dawkins, John Anthony Millman, Joseph Frederick Williamson, Patrick Robert Carnegie
-
Patent number: 9183503Abstract: Systems and methods are provided for identifying combinatorial feature interactions, including capturing statistical dependencies between categorical variables, with the statistical dependencies being stored in a computer readable storage medium. A model is selected based on the statistical dependencies using a neighborhood estimation strategy, with the neighborhood estimation strategy including generating sets of arbitrarily high-order feature interactions using at least one rule forest and optimizing one or more likelihood functions. A damped mean-field approach is applied to the model to obtain parameters of a Markov random field (MRF); a sparse high-order semi-restricted MRF is produced by adding a hidden layer to the MRF; indirect long-range dependencies between feature groups are modeled using the sparse high-order semi-restricted MRF; and a combinatorial dependency structure between variables is output.Type: GrantFiled: June 3, 2013Date of Patent: November 10, 2015Assignee: NEC Laboratories America, Inc.Inventors: Renqiang Min, Yanjun Qi
-
Patent number: 9175278Abstract: We describe a method of expressing a recombinant protein comprising mannose-terminated N-glycans from a host cell, the method comprising: (a) introducing a nucleic acid encoding a recombinant protein into a Chinese Hamster Ovary (CHO) cell comprising a mutation in the GnT 1 gene (GenBank Accession Number AF343963) leading to loss of GnT 1 function; and (c) expressing the recombinant protein from the host cell, in which the expressed recombinant protein comprises a mannose-terminated glycan structure, and in which the method does not include a step of introducing functional GnT-1 into the host cell. The method may be used for producing recombinant glucocerebrosidase with a mannose-terminated glycan structure, suitable for treatment or prevention of Gaucher's Disease.Type: GrantFiled: March 24, 2011Date of Patent: November 3, 2015Assignee: Agency for Science, Technology and ResearchInventor: Zhiwei Song
-
Patent number: 9169487Abstract: Disclosed is a technique which is for duplicating across a wide region any large region on a chromosome of a fungus belonging to Aspergillus strain, and which enables the stable and systematic acquisition of a previously un-acquirable fungus belonging to the Aspergillus strain having novel traits. Disclosed is a transformant wherein a transformation marker gene sequence is arranged on the outside of terminals (5?, 3?) of a region so as to sandwich an arbitrary region of a chromosome, and chromosome duplication has taken place by means of homologous recombination after double strand breakage generated in a homologous region inside the gene. Also disclosed is a method for duplicating an arbitrary region of a chromosome of a fungus belonging to Aspergillus strain by culturing said transformant.Type: GrantFiled: May 25, 2011Date of Patent: October 27, 2015Assignee: KIKKOMAN CORPORATIONInventor: Tadashi Takahashi
-
Patent number: 9168261Abstract: Autologous compositions and methods are provided for cartilage repair in patients in need thereof. Some aspects include combinations of platelet-based materials with chondrogenesis inducing agents in the presence or absence of cell-based therapies.Type: GrantFiled: June 28, 2013Date of Patent: October 27, 2015Assignee: Regenerative Sciences, LLCInventor: Christopher J. Centeno
-
Patent number: 9163257Abstract: A process for high expression of protein of interest using an expression vector. The process comprises at least the following regulatory elements: a) a CMV promoter, or its functional variants, b) an intron, c) TPL or its functional variants, d) VA genes or functional variants, and e) a bovine growth hormone polyadenylation sequence or functional variants.Type: GrantFiled: June 19, 2006Date of Patent: October 20, 2015Assignee: Cadila Healthcare LimitedInventors: Arun K. Singh, Ashish Goel, Sanjeev K. Mendiratta
-
Patent number: 9163270Abstract: A method of producing hyaluronic acid (HA) in Escherichia coli and Bacillus megaterium through episomal plasmid vectors wherein the gene is under the control of strong promoter T7, preferably under the control of strong promoter T7 of bacteriophage T7, and a system for the selection of stable bacterial strains producing high levels of hyaluronic acid, are provided.Type: GrantFiled: September 9, 2011Date of Patent: October 20, 2015Assignee: FIDIA FARMACEUTICI S.P.A.Inventors: Vincenza Corsa, Alessandro Negro, Sonia Bisicchia
-
Patent number: 9163256Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.Type: GrantFiled: August 20, 2007Date of Patent: October 20, 2015Assignee: Intrexon CorporationInventors: Subba Reddy Palli, Mohan Basavaraju Kumar
-
Patent number: 9150906Abstract: A method of determining whether or not a nucleic acid having an expected sequence or one or more variants of the expected sequence are present in a sample containing nucleic acids after replication, transcription or editing (or other transformation) of a substrate nucleic acid. The method involves deciding an expected sequence likely to be formed in the sample upon the replication, transcription or editing of the substrate nucleic acid, and possible variants of the expected sequence, providing primer pairs for a polymerase chain reaction, reverse transcriptase polymerase chain reaction or ligase chain reaction, carrying out the polymerase chain reaction or reverse transcriptase polymerase chain reaction in one or more steps to form amplicons, and analyzing the amplicons to determining whether or not a nucleic acid having the expected sequence and/or variants are present in the sample.Type: GrantFiled: June 28, 2006Date of Patent: October 6, 2015Assignee: BIO-ID DIAGNOSTIC INC.Inventor: Thuraiayah Vinayagamoorthy
-
Patent number: 9150628Abstract: The present invention relates to new inhibitors of the nucleic enzyme poly(adenosine 5?-diphospho-ribose) polymerase [“poly(ADP-ribose) polymerase” or “PARP”, which is also sometimes called “PARS” for poly(ADP-ribose) synthetase].Type: GrantFiled: November 14, 2006Date of Patent: October 6, 2015Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventor: Ali Hamiche
-
Patent number: 9150831Abstract: Disclosed are methods for conditionally immortalizing stem cells, including adult and embryonic stem cells, the cells produced by such methods, therapeutic and laboratory or research methods of using such cells, and methods to identify compounds related to cell differentiation and development or to treat diseases, using such cells. A mouse model of acute myeloid leukemia (AML) and cells and methods related to such mouse model are also described.Type: GrantFiled: February 5, 2010Date of Patent: October 6, 2015Assignees: The Regents of the University of Colorado, National Jewish HealthInventors: John C. Cambier, Yosef Refaeli, Sara Ann Johnson, Brian Curtis Turner
-
Patent number: RE45721Abstract: Disclosed are libraries of DNA sequences encoding zinc finger binding motifs for display on a particle, together with methods of designing zinc finger binding polypeptides for binding to a particular target sequence and, inter alia, use of designed zinc finger polypeptides for various in vitro or in vivo applications.Type: GrantFiled: March 25, 2003Date of Patent: October 6, 2015Assignee: GENDAQ, LTD.Inventors: Yen Choo, Aaron Klug, Isidro Sanchez-Garcia
-
Patent number: RE45795Abstract: Disclosed are libraries of DNA sequences encoding zinc finger binding motifs for display on a particle, together with methods of designing zinc finger binding polypeptides for binding to a particular target sequence and, inter alia, use of designed zinc finger polypeptides for various in vitro or in vivo applications.Type: GrantFiled: December 3, 2002Date of Patent: November 10, 2015Assignee: GENDAQ, LTD.Inventors: Yen Choo, Aaron Klug, Isidro Sanchez-Garcia